Conditions

This post was originally published on this site Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation titled, “Overall survival (OS) results of the phase III…

This post was originally published on this site Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant or intolerant to combination therapy with fluoropyrimidine and platinum-based treatments, the ATTRACTION-3 clinical trial shows. Opdivo demonstrated a…

This post was originally published on this site The Myeloma Crowd is inviting multiple myeloma patients with psoriasis to join a new study to uncover possible correlations between the two disorders. Study participation is through Myeloma Crowd’s HealthTree platform, where more than 4,500 myeloma patients are currently registered. Launched last fall, the free digital tool…

This post was originally published on this site Maintenance treatment with Zejula (niraparib) prolongs the time lived without disease worsening in women with newly diagnosed advanced ovarian cancer who are responding to their first-line platinum-based chemotherapy — regardless of mutations in DNA repair genes — a Phase 3 clinical trial has shown. Patients treated with…

This post was originally published on this site Men who see their prostate cancer returning after surgery see no benefits from adding long-term hormone therapy to salvage radiation therapy if their PSA levels are low; instead, they might be at higher risk of dying from causes other than cancer, like cardiac or neurological problems, a…

This post was originally published on this site To allow patients to focus on treatment and not cost, the HealthWell Foundation is offering copayment and insurance premium assistance to people with mantle cell lymphoma (MCL) who are on Medicare. The non-profit organization will provide up to $8,500 in financial aid as a yearlong grant to…

This post was originally published on this site Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without compromising their quality of life — a Phase 3 clinical trial shows. Those findings were presented in the…

This post was originally published on this site Adding the immunotherapy Keytruda (pembrolizumab) to chemotherapy increases the number of women with early triple-negative breast cancer who clear all signs of cancer, and tends to prolong survival without complications or symptoms, according to the latest results from the KEYNOTE-522 trial. “The data suggest that the improved pathological…

This post was originally published on this site A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences announced. Galinpepimut-S is a cancer vaccine developed by Sellas to target the Wilms tumor 1 (WT1) protein. WT1…

This post was originally published on this site People with non-Hodgkin’s lymphoma who are HIV-positive and have not received antiretroviral therapy — a treatment that stops HIV from replicating — have similar outcomes on standard R-CHOP chemotherapy, compared to those who have already started their HIV treatment, a retrospective study found. The study suggests that HIV-positive…